BioCentury

7:00 AM GMT, Aug 15, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Status

Rhucin: SPA received

Pharming received an SPA from FDA after amending the protocol for an ongoing, double-blind, placebo-controlled Phase III trial evaluating IV Rhucin. In

Read the full 229 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.